替吉奥联合阿帕替尼治疗晚期胰腺癌的疗效分析

目的 探讨替吉奥联合阿帕替尼治疗晚期胰腺癌的临床疗效。方法 选取2016年5月~2018年5月我院收治的100例晚期胰腺癌患者作为研究对象，按照数字随机分为对照组和研究组，每组50例。对照组采用阿帕替尼治疗，研究组采用替吉奥联合阿帕替尼治疗，比较两组PR、PD及化疗后血常规、肝功、不良反应情况。结果 研究组PR、SD分别为46.00%、28.00%，多于对照组的26.00%、6.00%，差异有统计学意义（P＜0.05）；研究组PD占26.00%，少于对照组的68.00%，差异有统计学意义（P＜0.05）。研究组白细胞减少、中性粒细胞减少、血小板减少、贫血、乏力、厌食、氨基转移酶升高、腹泻均低于对照组，差异有统计学意义（P＜0.05）；研究组5个月、10个月、15个月的无进展生存率，均高于对照组，差异有统计学意义（P＜0.05）。结论 替吉奥联合阿帕替尼治疗晚期胰腺癌有利于改善患者的临床症状，降低不良反应发生率，延长患者生命。

Therapeutic Effect of Tiggio Combined with Apatinib in the Treatment of Advanced Pancreatic Cancer

Abstract:Objective To investigate the clinical efficacy of tiggio combined with apatinib in the treatment of advanced pancreatic cancer.Methods A total of 100 patients with advanced pancreatic cancer admitted to our hospital from May 2016 to May 2018 were randomly divided into the control group and the study group,50 patients in each group.The control group was treated with apatinib,the study group was treated with tiggio combined with apatinib,and the PR,PD,blood routine,liver function and adverse reactions were compared between the two groups.Results The PR and SD of the study group were 46.00% and 28.00%,respectively,which were more than 26.00% and 6.00% of the control group,the difference was statistically significant(P<0.05).The PD of the study group accounted for 26.00%,which was less than 68.00% of the control group,the difference was statistically significant(P<0.05).The study group leukopenia,neutropenia,thrombocytopenia,anemia,fatigue,anorexia,elevated aminotransferase,diarrhea were lower than the control group, the difference was statistically significant(P<0.05);the study group 5 months,the progression-free survival rate at 10 months and 15 months was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Tiggio combined with apatinib in the treatment of advanced pancreatic cancer is beneficial to improve the clinical symptoms,reduce the incidence of adverse reactions and prolong the life of patients.